https://www.selleckchem.com/products/d-ap5.html
In the CARD study (NCT02485691), cabazitaxel significantly improved median radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel and progressed ≤12 mo on the alternative agent (abiraterone/enzalutamide). To assess cabazitaxel versus abiraterone/enzalutamide in older (≥70yr) and younger (70yr) patients in CARD. Patients with mCRPC were randomized 11 to cabazitaxel (25mg/m plus
Like
Comment
Share
